499 results on '"B. Bodaghi"'
Search Results
2. Disminución repentina de la agudeza visual
- Author
-
H. Zeghidi, P. LeHoang, and B. Bodaghi
- Subjects
Ocean Engineering ,Safety, Risk, Reliability and Quality - Published
- 2023
3. Lupus érythémateux disséminé et rétinopathie ischémique : à propos d’un cas
- Author
-
M.-G. Desurmont, T. Sales de Gauzy, A. Toutée, D. Lam, C. Fardeau, and B. Bodaghi
- Subjects
Ophthalmology - Published
- 2022
4. Belatacept and CMV: Severe retinitis and vascular complications, case report
- Author
-
P.-L. Meurisse, T. Sales de Gauzy, and B. Bodaghi
- Subjects
Ophthalmology - Published
- 2022
5. Chirurgie sur l’œil inflammatoire, perspectives
- Author
-
B. Bodaghi, A. Mainguy, and S. Touhami
- Subjects
General Medicine - Published
- 2022
6. Early symptomatic neurosyphilis and ocular syphilis: A comparative study between HIV-positive and HIV-negative patients
- Author
-
Vero Rasoldier, Luc Paris, Martine Pestel-Caron, M. Muraine, B. Bodaghi, François Caron, C. Chapuzet, J. Gueudry, Roland Tubiana, Eric Caumes, Hôpital Charles Nicolle [Rouen], Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Reims Champagne-Ardenne (URCA), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), VILLIER, Venceslas, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual acuity ,Visual Acuity ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Eye Infections, Bacterial ,Ocular syphilis ,Serology ,Uveitis ,Neurosyphilis ,Sexual and Gender Minorities ,03 medical and health sciences ,Cerebrospinal fluid ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,HIV Seropositivity ,medicine ,Humans ,Meningitis ,Paresthesia ,Syphilis ,ocular syphilis ,0303 health sciences ,030306 microbiology ,business.industry ,Cranial Nerves ,HIV ,Middle Aged ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Treatment Outcome ,Infectious Diseases ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,medicine.symptom ,business - Abstract
International audience; Objectives: Since the 2000s, there has been an increase in prevalence of neurosyphilis (NS) and ocular syphilis (OS). As data about symptomatic NS/OS is limited, this study aims to assess the characteristics of symptomatic NS/OS, according to HIV status.Methods: We compared the clinical and biological presentation of early symptomatic NS/OS and its outcome in HIV-positive and HIV-negative patients.Results: Ninety-six patients (93% men, 49% HIV-positive) were included from 2000 to 2016 in two centers, with 67 (69%) having OS, 15 (16%) NS, and 14 (14%) both. HIV-positive patients were younger (P = 0.006) and more likely to be males having sex with males (P = 0.00048) or to have a history of syphilis (P = 0.01). Among 81 OS, there were 43 posterior uveitis (57%), and bilateral involvement was more common in HIV-positive patients (62% versus 38%, P = 0.045). Among 29 NS there were 21 cases of cranial nerve involvement (72%), seven meningitis (24%) and 11 paresthesia (38%). Involvement of the VIIIth cranial nerve was the most common (16 cases). Treponemal tests were more commonly found positive in cerebrospinal fluid in HIV-positive patients (88% versus 76%, P = 0.04). Visual acuity (VA) always improved after treatment (initial VA logMAR 0.8 ± 0.8 versus 0.1 ± 0.1 at 3 months), but 32% and 18% of the patients still had neurological or ocular impairment respectively six and 12 months after treatment. Non-treponemal serological reversion was observed in 43/50 patients (88%) at six months.Conclusion: HIV infection has no consequence on the outcome of NS and OS. Sequelae are common, emphasizing the importance of prevention, and screening, and questioning enhanced treatment.
- Published
- 2021
7. Uveítis
- Author
-
H. Zeghidi, P. LeHoang, and B. Bodaghi
- Published
- 2020
8. Prise en charge de la toxoplasmose oculaire en France : résultats d’une étude Delphi modifiée
- Author
-
M. Schaeffer, L. Ballonzoli, D. Gaucher, C. Arndt, K. Angioi-Duprez, R. Baudonnet, B. Bodaghi, A. Bron, F. Chiambaretta, B. Cimon, C. Chiquet, C. Creuzot-Garcher, V. Daien, A.-S. Deleplanque, H. Fricker-Hidalgo, E. Hadjadj, S. Houze, T. Ifrah, J.-F. Korobelnik, P. Labalette, M.-Laure Le Lez, C. L’Ollivier, M. Mercie, F. Mouriaux, L. Paris, H. Pelloux, C. Pomares, J.-C. Quintyn, M.-B. Rougier, A. Rousseau, V. Soler, M. Talmud, I. Villena, O. Villard, C. Speeg-Schatz, T. Bourcier, A. Sauer, Infections Respiratoires Fongiques (IRF), Université d'Angers (UA), SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Laboratoire de Parasitologie-Mycologie (CHU d'Angers), Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)
- Subjects
Ophthalmology ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2022
9. Anti-TNF alpha versus Tocilizumab dans la prise en charge des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS
- Author
-
G. Maalouf, A. Anais, L. Mathilde, P. Sève, P. Bielefeld, G. Julie, S. Thomas, C. Titah, T. Moulinet, B. Rouviere, D. Sene, D. Anne-Claire, F. Domont, T. Sarah, C. Patrice, K. Laurent, L. Biard, B. Bodaghi, and D. Saadoun
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2022
10. Effet bénéfique du traitement immunosuppresseur dans les uvéites non-antérieures de la sarcoïdose
- Author
-
M. Leclercq, P. Sève, L. Biard, M. Vautier, F. Domont, G. Maalouf, G. Leroux, A. Toutée, C. Fardeau, S. Touhami, B. Bodaghi, L. Kodjikian, P. Cacoub, D. Saadoun, and A.C. Desbois
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2022
11. [Management of ocular toxoplasmosis in France: Results of a modified Delphi study]
- Author
-
M, Schaeffer, L, Ballonzoli, D, Gaucher, C, Arndt, K, Angioi-Duprez, R, Baudonnet, B, Bodaghi, A, Bron, F, Chiambaretta, B, Cimon, C, Chiquet, C, Creuzot-Garcher, V, Daien, A-S, Deleplanque, H, Fricker-Hidalgo, E, Hadjadj, S, Houze, T, Ifrah, J-F, Korobelnik, P, Labalette, M-Laure, Le Lez, C, L'Ollivier, M, Mercie, F, Mouriaux, L, Paris, H, Pelloux, C, Pomares, J-C, Quintyn, M-B, Rougier, A, Rousseau, V, Soler, M, Talmud, I, Villena, O, Villard, C, Speeg-Schatz, T, Bourcier, and A, Sauer
- Subjects
Delphi Technique ,Recurrence ,Trimethoprim, Sulfamethoxazole Drug Combination ,Humans ,Azithromycin ,Toxoplasmosis, Ocular - Abstract
To evaluate diagnostic and therapeutic practices and then establish a consensus on the management of ocular toxoplasmosis in France through a Delphi study.Twenty-three French experts in ocular toxoplasmosis were invited to respond to a modified Delphi study conducted online, in the form of two questionnaires, in an attempt to establish a consensus on the diagnosis and management of this pathology. The threshold for identical responses to reach consensus was set at 70 %.The responses of 19 experts out of the 23 selected were obtained on the first questionnaire and 16 experts on the second. The main elements agreed upon by the experts were to treat patients with a decrease in visual acuity or an infectious focus within the posterior pole, to treat peripheral lesions only in the presence of significant inflammation, the prescription of first-line treatment with pyrimethamine-azithromycin, the use of corticosteroid therapy after a period of 24 to 48hours, the prophylaxis of frequent recurrences (more than 2 episodes per year) with trimethoprim-sulfamethoxazole as well as the implementation of prophylactic treatment of recurrences in immunocompromised patients. On the other hand, no consensus emerged with regard to the examinations to be carried out for the etiological diagnosis (anterior chamber paracentesis, fluorescein angiography, serology, etc.), second-line treatment (in the case of failure of first-line treatment), or treatment of peripheral foci.This study lays the foundations for possible randomized scientific studies to be conducted to clarify the management of ocular toxoplasmosis, on the one hand to confirm consensual clinical practices and on the other hand to guide practices for which no formal consensus has been demonstrated.
- Published
- 2021
12. Uvéites chez les patients vivant avec le VIH : une étude rétrospective multicentrique
- Author
-
M. Razafinimanana, L. Benjamin, D. Saadoun, B. Bodaghi, A. Toutée, E. Caumes, C. Katlama, V. Pourcher, P. Sève, L. Cotte, L. Kodjikian, Y. Serrar, H. Devilliers, P. Bielefeld, S. Mouries-Martin, R. Jaussaud, K. Angioi-Duprez, and T. Moulinet
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2022
13. [Snowy exudates in a branch retinal vein occlusion]
- Author
-
A, Mainguy, B, Bodaghi, and C, Fardeau
- Subjects
Retinal Vein Occlusion ,Humans ,Exudates and Transudates ,Fluorescein Angiography ,Retinal Vein - Published
- 2020
14. [Categorization of the degree of urgency according to ophthalmology procedures or situations]
- Author
-
C, Arndt, F, Audrun, B, Bodaghi, J-P, Caujolle, N, Cassoux, S, Defoort, M-N, Delyfer, P, Denis, S, Doan, J-R, Fenolland, J-M, Giraud, L, Kodjikian, M, Labetoulle, J, Lasudry, N, Leveziel, A, Rousseau, D, Saadoun, C, Speeg-Schatz, S, Touhami, V, Touitou, C, Vignal, and C, Zech
- Subjects
Adult ,Operating Rooms ,Eye Diseases ,Pneumonia, Viral ,Infant, Newborn ,COVID-19 ,Infant ,Ophthalmologic Surgical Procedures ,Severity of Illness Index ,Ophthalmology ,Child, Preschool ,Humans ,Emergencies ,Triage ,Child ,Coronavirus Infections ,Pandemics - Published
- 2020
15. [How to approach follow-up of uveitis patients during the Covid-19 pandemic?]
- Author
-
S, Touhami, D, Saadoun, L, Kodjikian, and B, Bodaghi
- Subjects
SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Antiviral Agents ,Uveitis, Anterior ,Telemedicine ,Article ,Hospitalization ,Uveitis ,Betacoronavirus ,Withholding Treatment ,Recurrence ,Intravitreal Injections ,Ambulatory Care ,Humans ,Steroids ,Coronavirus Infections ,Pandemics ,Immunosuppressive Agents ,Scleritis - Published
- 2020
16. [Observational study of QuantiFERON® management for ocular tuberculosis diagnosis: Analysis of 244 consecutive tests]
- Author
-
A, Amara, E, Ben Salah, A, Guihot, C, Fardeau, V, Touitoue, D, Saadoun, B, Bodaghi, P, Sève, and S, Trad
- Subjects
Adult ,Uveitis ,Tuberculin Test ,Humans ,Prospective Studies ,Tuberculosis, Ocular ,Middle Aged ,Interferon-gamma Release Tests ,Scleritis - Abstract
Ocular tuberculosis (TB) diagnosisremains difficult and quantiferon (QFT) contribution needs still yet to be specified, despite its generalization in France. The purpose of this observational study is to assess in which ocular inflammation (OI) presentation QFT is prescribed and to evaluate the added value of new QuantiFERON®-TB Gold Plus (QFT-Plus) test for diagnosis ocular TB diagnosis.Monocentric, observational study, carried out in an ophthalmology department over a period of 5 months. Inclusion criteria were defined as an existence of an OI for which a QFT-Plus test was part of the etiological investigations. Of the 316 consecutive files, 72 were excluded (indeterminate test, prescription before anti-TNFα or immunosuppressant initiation, missing data, wrong indication) and 244 were selected and divided into two groups: group one (anterior uveitis/episcleritis, n=129) and group two (intermediate/posterior uveitis/optic neuritis/ocular myositis, n=115). All positive QFT patients underwent an etiological investigation including thoracic imaging.Forty-five patients, aged 52±12 years, had positive QFT (18.5%), including 18 patients for group 1 and 27 for group 2. Living in TB-endemic area, TB exposure and chest imaging abnormalities were identified in 70%, 27% and 22% of cases, respectively. OI was chronic in 36% of cases (group one, 4/18; group two, 12/27). None of the 18 patients, in group 1, received anti-tuberculosis treatment (ATT) or experienced a relapse during one-year follow-up. Four QFT+ patients, from group 2 (15%) had another associated disease explaining their uveitis. Among the 23 other patients without identified etiology, 13 had at least one relevant ophthalmological signs predictive of TB uveitis (posterior synechiae, retinal vasculitis and/or choroidal granuloma) (59%). Eleven patients received a 6-month ATT trial. Radiological abnormalities and granulomas at angiography were significantly more frequent among treated patients (p=0.03 and 0.001, respectively). A full OI recovery was observed for 8 patients (73%), considered ex-post as ocular TB. Nine patients in group 2 received rifampicin/isoniazid dual therapy for 3 months, but no conclusion could be drawn as to the benefit of such prescription on OI. QFT rate comparison, according to CD4 stimulation by ESAT-6/CFP-10 peptides or by CD4/CD8 co-stimulation, was comparable and found only 4 cases of discrepancy (1.6%). None of these 4 cases had ocular TB diagnosis.Positive QFT frequency among patients consulting for posterior OI remains high. In this study, radiological abnormalities and granulomas at angiography seemed to be more closely related to clinician decision for starting ATT trial in QFT+ patients, which was effective in 73% of cases. QFT-Plus does not seem more relevant than QFT-TB in exploring an OI. Prospective studies are necessary to codify QFT management in the etiological assessment of OI and clearly define ATT trial indications as well as their modalities.
- Published
- 2020
17. [The invisible enemy]
- Author
-
B, Bodaghi
- Subjects
Aged, 80 and over ,Coinfection ,SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Comorbidity ,History, 20th Century ,History, 21st Century ,Severity of Illness Index ,Betacoronavirus ,Influenza A Virus, H1N1 Subtype ,Influenza, Human ,Humans ,Coronavirus Infections ,Epidemics ,Asymptomatic Infections ,Pandemics ,Aged - Published
- 2020
18. Tuberculose oculaire
- Author
-
S. Trad, D. Saadoun, M.H. Errera, S. Abad, P. Bielefeld, C. Terrada, D. Sène, B. Bodaghi, and P. Sève
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2018
19. Les manifestations oculaires de la maladie de Behçet
- Author
-
A.-C. Desbois, C. Terrada, P. Cacoub, B. Bodaghi, and D. Saadoun
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2018
20. Cataratas
- Author
-
S. Touhami and B. Bodaghi
- Published
- 2018
21. [Experts' opinion: Updating good practices for intra-vitreous injection. Recommendations of the French Ophthalmology Societythe French Hospital Hygiene Society]
- Author
-
S-Y, Cohen, L, Kodjikian, F, Devin, M-N, Delyfer, C, Dot, H, Oubraham, S, Razavi, R, Tadayoni, B, Bodaghi, L-S, Aho, A-M, Rogues, M, Soulias-Leveziel, and J-F, Korobelnik
- Subjects
Ophthalmology ,Safety Management ,Intravitreal Injections ,Humans ,Hygiene ,France ,Anesthetics, Local ,Practice Patterns, Physicians' ,Expert Testimony ,Hospitals ,Societies, Medical ,Checklist ,Monitoring, Physiologic - Published
- 2019
22. [Erratum to 'Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies' [Med. Mal. Infect. 49 (2019) 296-317]]
- Author
-
Figoni J, Carole Eldin, Catherine Chirouze, Gerard Lina, J F Gehanno, B Bodaghi, Gocko X, Pierre Tattevin, Nathalie Boulanger, Monsuez Jj, Henri Partouche, Yves Hansmann, F. Roblot, Sellal F, Benoît Jaulhac, A. Raffetin, Perrot S, Eric Caumes, F Vuillemet, Sobas C, Olivier Picone, Cathebras P, Jean-Pierre Gangneux, Maël Dieudonné, Kevin Bouiller, Bruno Fantin, Cédric Lemogne, Catherine Michel, Brigitte Degeilh, Albert Sotto, Hentgen, Cédric Lenormand, Christian Rabaud, A Saunier, Toubiana J, de Broucker T, C Sordet, CHU Rouen, Normandie Université (NU), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm - Paris Descartes), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Service de neurologie [CH Saint Denis], Centre Hospitalier de Saint-Denis [Ile-de-France], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Delafontaine, Hôpital de Hautepierre [Strasbourg], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Bactériologie, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon (HCL), CHU Strasbourg, Centre de Référence des Maladies AutoInflammatoires (CeRéMAI), Centre Hospitalier de Versailles André Mignot (CHV), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Max Weber (CMW), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), Service de Parasitologie-Mycologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Intercommunal Villeneuve-Saint-Georges (CHIV), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Laboratoire Chrono-environnement (UMR 6249) (LCE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Haut Conseil de la Santé Publique, Service de neurologie, Hôpital de Saint-Denis, Service de Neurologie [Strasbourg], CHU Strasbourg-Hopital Civil, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Anofel Cryptosporidium National Network, Centre de Physique Théorique [Palaiseau] (CPHT), École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Estación Biológica de Doñana CSIC (SPAIN), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)
- Subjects
0303 health sciences ,Tick-borne disease ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,030306 microbiology ,Lyme borreliosis ,business.industry ,medicine.disease ,Virology ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,medicine ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030212 general & internal medicine ,business ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2019
23. Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosis
- Author
-
Figoni J, Jean-Pierre Gangneux, Perrot S, Pierre Tattevin, Henri Partouche, J F Gehanno, Maël Dieudonné, B Degeilh, Benoît Jaulhac, Kevin Bouiller, Olivier Picone, Catherine Michel, Yves Hansmann, A Saunier, Nathalie Boulanger, T. de Broucker, Eric Caumes, Bruno Fantin, Monsuez Jj, Cathebras P, Julie Toubiana, A. Raffetin, F Vuillemet, François Sellal, Carole Eldin, Cédric Lenormand, C Sordet, Cédric Lemogne, Albert Sotto, V Hentgen, Catherine Chirouze, Gerard Lina, F. Roblot, Christian Rabaud, B Bodaghi, Gocko X, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Service de maladies infectieuses et tropicales, Hôpital de Hautepierre [Strasbourg], Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Référence des Maladies AutoInflammatoires (CeRéMAI), Centre Hospitalier de Versailles André Mignot (CHV), Service central de médecine du travail de l'AP-HP, Hôtel Dieu de Paris, Haut Conseil de la Santé Publique, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Service de neurologie, Hôpital de Saint-Denis, CHU Strasbourg, Médecine interne [ Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de Neurologie [Strasbourg], CHU Strasbourg-Hopital Civil, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Centre National de référence des Staphylocoques, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL), Centre Max Weber (CMW), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), Service de Parasitologie-Mycologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Rouen, Normandie Université (NU), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre Hospitalier Intercommunal Villeneuve-Saint-Georges (CHIV), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et réanimation médicale, and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou
- Subjects
Societies, Scientific ,Pediatrics ,medicine.medical_specialty ,Ixodes ricinus ,Prévention ,Human granulocytic anaplasmosis ,Erythema migrans ,Tick ,Borréliose de Lyme ,03 medical and health sciences ,Lyme disease ,Ticks ,Babesiosis ,Érythème migrant ,Medicine ,Animals ,Humans ,Tiques ,Lyme borreliosis ,0303 health sciences ,Tick-borne disease ,Lyme Disease ,biology ,Ixodes ,030306 microbiology ,business.industry ,Neuroborreliosis ,Arthritis ,Tick-borne encephalitis ,Skin Diseases, Bacterial ,medicine.disease ,biology.organism_classification ,3. Good health ,Infectious Diseases ,Rickettsiosis ,Arthrite ,Tick-Borne Diseases ,Practice Guidelines as Topic ,France ,business ,Encephalitis, Tick-Borne ,Neuroborréliose ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Lyme borreliosis is transmitted en France by the tick Ixodes ricinus, endemic in metropolitan France. In the absence of vaccine licensed for use in humans, primary prevention mostly relies on mechanical protection (clothes covering most parts of the body) that may be completed by chemical protection (repulsives). Secondary prevention relies on early detection of ticks after exposure, and mechanical extraction. There is currently no situation in France when prophylactic antibiotics would be recommended. The incidence of Lyme borreliosis in France, estimated through a network of general practitioners (réseau Sentinelles), and nationwide coding system for hospital stays, has not significantly changed between 2009 and 2017, with a mean incidence estimated at 53 cases/100,000 inhabitants/year, leading to 1.3 hospital admission/100,000 inhabitants/year. Other tick-borne diseases are much more seldom in France: tick-borne encephalitis (around 20 cases/year), spotted-fever rickettsiosis (primarily mediterranean spotted fever, around 10 cases/year), tularemia (50-100 cases/year, of which 20% are transmitted by ticks), human granulocytic anaplasmosis (
- Published
- 2019
24. Safe short circuit in cataract surgery: Incidence and risk factors for intraoperative medical action
- Author
-
M.-D. Rossignon, B. Bodaghi, S. Bonnin, R. Rigolot, A. Khorrami, V. Touitou, A. L. Remond, A. Jacquens, N. Butel, Vincent Degos, and M. Toulemont
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Cataract Extraction ,Critical Care and Intensive Care Medicine ,Cataract ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,Medical history ,030212 general & internal medicine ,Retrospective Studies ,Surgical team ,business.industry ,Incidence (epidemiology) ,Incidence ,Case-control study ,030208 emergency & critical care medicine ,General Medicine ,Odds ratio ,Perioperative ,Cataract surgery ,Surgery ,Anesthesiology and Pain Medicine ,Case-Control Studies ,Observational study ,business - Abstract
Cataract surgery has become the most frequent surgical procedure performed every year in Western countries. Perioperative patient circuit has to be adapted to the important medical needs and progress. Hence, a secure short circuit (SSC) for surgeries of the anterior segment of the eye under topical anaesthesia was created. Patients included in the circuit are selected first by surgeons and answer a medical questionnaire, they do not have any preoperative evaluation by anaesthesiologist, are monitored during surgery by the surgical team and in case of problem an intraoperative medical action (IMA) can be performed. We conducted a retrospective observational incidence study of the occurrence of the IMA, followed by a case control study. The primary outcome was to identify risk factors of IMA among the patients’ medical history. Out of 2744 screened patients, 1592 patients were included during the period of November 2015 to November 2017. The rate of IMA was 5%, 81% of them presenting with intraoperative high blood pressure (HBP). In the case control study part, stepwise regression analysis revealed that a history of HBP and insulin-dependent diabetes (IDD) was significantly correlated with IMA (respectively, adjusted odds ratio 1.7, P = 0.005 and 2.6, P = 0.002). The low incidence of IMA showed that the SSC is a safe tool thanks to a selection and an optimised and secure pathway. A history of HBP and IDD was significantly associated with the occurrence of IMA. Therefore, an optimisation of the perioperative period would be beneficial in these cases.
- Published
- 2019
25. [Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]
- Author
-
C, Couret, J-B, Ducloyer, S, Touhami, K, Angioi-Duprez, M-B, Rougier, P, Labalette, C, Titah, I, Cochereau, L, Kodjikian, F, Mura, C, Chiquet, M, Weber, and B, Bodaghi
- Subjects
Panuveitis ,Vision Disorders ,Humans ,Uveitis, Posterior ,Glucocorticoids ,Uveitis, Intermediate ,Immunosuppressive Agents ,Tomography, Optical Coherence - Abstract
Controlling long-term inflammation during non-infectious intermediate, posterior or panuveitis while limiting side effects remains challenging. There is no standardized pre-therapeutic evaluation providing diagnostic certainty, but some simple tests allow us to identifiy the main etiologies. The ophthalmologist identifies the type of uveitis, and the internist completes the investigations according to the ophthalmologist's findings. Fundus photographs, optical coherence tomography, and fluorescein and indocyanine green angiography should be considered during diagnosis and follow-up. Ocular complications of uveitis are numerous. They require close monitoring and specific medical and sometimes surgical management. The growing number of available drugs makes it possible to optimize the management of these conditions with varied etiologies and presentations. Currently, systemic corticosteroids remain the mainstay of therapy, and other alternatives are considered in the case of poor tolerance, steroid resistance or dependence. The choice of a systemic, periocular or intravitreal treatment depends on several factors: chronicity or recurrence of uveitis, duration, bilaterality, association with a systemic inflammatory disease, the presence of contraindications to certain treatments, and also socioeconomic constraints. It is of the utmost importance to find the best compromise allowing tight control of ocular inflammation by means of adapted systemic and/or local treatment while avoiding the main complications.
- Published
- 2019
26. Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis
- Author
-
C Sordet, Carole Eldin, Figoni J, Cathebras P, Pierre Tattevin, Yves Hansmann, Brigitte Degeilh, Sobas C, Maël Dieudonné, Julie Toubiana, Perrot S, Eric Caumes, Benoît Jaulhac, V Hentgen, N Boulanger, Jean-Jacques Monsuez, F. Roblot, Jean-François Gehanno, B Bodaghi, Cédric Lemogne, Gocko X, A Saunier, F Vuillemet, Olivier Picone, Christian Rabaud, T. de Broucker, Albert Sotto, endorsed by scientific societies, Catherine Chirouze, Cédric Lenormand, Catherine Michel, François Sellal, Gerard Lina, Kevin Bouiller, Bruno Fantin, A. Raffetin, Jean-Pierre Gangneux, Henri Partouche, CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de santé au travail et pathologie professionnelle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de Hautepierre [Strasbourg], Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Max Weber (CMW), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm - Paris Descartes), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pitié-Salpêtrière [APHP], Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM)
- Subjects
Societies, Scientific ,medicine.medical_specialty ,Erythema migrans ,[SDV]Life Sciences [q-bio] ,Aucun ,Western blot ,Serology ,Diagnosis, Differential ,Borréliose de Lyme ,03 medical and health sciences ,medicine ,Érythème migrant ,Animals ,Humans ,Seroconversion ,ComputingMilieux_MISCELLANEOUS ,Lyme borreliosis ,Symptomatologie somatique persistante ,Doxycycline ,Lyme Disease ,0303 health sciences ,Tick-borne disease ,Clinical Laboratory Techniques ,030306 microbiology ,business.industry ,Neuroborreliosis ,Amoxicillin ,medicine.disease ,Sciences du Vivant [q-bio]/Microbiologie et Parasitologie ,Dermatology ,Persistent somatic symptoms ,3. Good health ,LYME ,Infectious Diseases ,Tick-Borne Diseases ,Practice Guidelines as Topic ,Disease Progression ,France ,business ,Neuroborréliose ,medicine.drug - Abstract
The serodiagnosis of Lyme borreliosis is based on a two-tier strategy: a screening test using an immunoenzymatic technique (ELISA), followed if positive by a confirmatory test with a western blot technique for its better specificity. Lyme serology has poor sensitivity (30-40%) for erythema migrans and should not be performed. The seroconversion occurs after approximately 6 weeks, with IgG detection (sensitivity and specificity both>90%). Serological follow-up is not recommended as therapeutic success is defined by clinical criteria only. For neuroborreliosis, it is recommended to simultaneously perform ELISA tests in samples of blood and cerebrospinal fluid to test for intrathecal synthesis of Lyme antibodies. Given the continuum between early localized and disseminated borreliosis, and the efficacy of doxycycline for the treatment of neuroborreliosis, doxycycline is preferred as the first-line regimen of erythema migrans (duration, 14 days; alternative: amoxicillin) and neuroborreliosis (duration, 14 days if early, 21 days if late; alternative: ceftriaxone). Treatment of articular manifestations of Lyme borreliosis is based on doxycycline, ceftriaxone, or amoxicillin for 28 days. Patients with persistent symptoms after appropriate treatment of Lyme borreliosis should not be prescribed repeated or prolonged antibacterial treatment. Some patients present with persistent and pleomorphic symptoms after documented or suspected Lyme borreliosis. Another condition is eventually diagnosed in 80% of them. endorsed by scientific societies
- Published
- 2019
27. Efficacité du tocilizumab dans la prise en charge de l’œdème maculaire cystoïde et des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS
- Author
-
M. Leclercq, G. Maalouf, P. Sève, P. Bielefeld, B. Rouviere, N. Girszyn, T. Moulinet, J. Gueudry, T. Sené, D. Sene, P. Cacoub, F. Domont, A.C. Desbois, T. Sarah, B. Bodaghi, L. Biard, and D. Saadoun
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2020
28. [Ocular tuberculosis]
- Author
-
S, Trad, D, Saadoun, M H, Errera, S, Abad, P, Bielefeld, C, Terrada, D, Sène, B, Bodaghi, and P, Sève
- Subjects
Diagnosis, Differential ,Tuberculin Test ,Prevalence ,Humans ,Mycobacterium tuberculosis ,Tuberculosis, Ocular - Abstract
Despite extensive investigations, including the use of Interferon-gamma release assays (IGRA), the diagnosis of intraocular tuberculosis (TB) remains challenging. Ocular evidence of Mycobacterium tuberculosis in low endemic countries for TB is extremely rare, leading mostly to a TB-related ocular inflammation presumptive diagnosis. This present work aims: to highlights the main clinical patterns suggestive of ocular TB; and the latest recommended guidelines for diagnosing ocular TB to clarify interferon-gamma release assay (IGRA) contribution and accuracy to the management of intraocular TB and its diagnosis, in addition to other available diagnostic tools, such as tuberculin skin test, bacteriologic and histologic analysis from intra/extra ocular sample and radiographic investigations; to define the accuracy of these diagnostic tools according to the endemic TB prevalence; and finally to identify therapeutic strategies adapted to the main clinical presentations of ocular TB. Our review of the literature shows that management of suspected ocular TB differs significantly based on whether patients are from high or low TB prevalence countries since accuracy of chest X-ray, tuberculin skin test and IGRA is significantly different. Taking into account these discrepancies, distinct guidelines should be determined for managing patients with suspected ocular TB, taking into consideration home prevalence of TB-patients.
- Published
- 2018
29. [Uveitis: From diagnosis to treatment]
- Author
-
D, Saadoun, S, Trad, P, Bielfeld, D, Sene, S, Abad, G, Kaplanski, C, Terrada, L, Kodjikian, B, Bodaghi, and P, Seve
- Subjects
Biological Therapy ,Uveitis ,Prevalence ,Humans ,Diagnostic Techniques, Ophthalmological ,Immunosuppressive Agents - Published
- 2018
30. [Ocular manifestations in Behçet's disease]
- Author
-
A-C, Desbois, C, Terrada, P, Cacoub, B, Bodaghi, and D, Saadoun
- Subjects
Diagnosis, Differential ,Eye Diseases ,Tumor Necrosis Factor-alpha ,Behcet Syndrome ,Vision Disorders ,Humans ,Diagnostic Techniques, Ophthalmological ,Immunosuppressive Agents - Abstract
Ocular disease in Behçet's disease is frequent and may be associated with a poor functional prognosis. Uveitis is the most common ocular manifestation in Behçet's disease and represents a diagnostic criterion of the disease. The ocular involvement is inaugural of the disease in 20% of the cases or may develop 2 to 3 years after the beginning of the extraocular signs. The risk of blindness at 5 years is in the order of 15 to 25%, mainly due to macular involvement or retinal vasculitis. Uveitis may be anterior, intermediate, posterior or panuveitis. Anterior uveitis is rarely isolated and is frequently accompanied by posterior involvement. Anterior uveitis is always non granulomatous, sometimes associated with hypopion. Posterior involvement may include the presence of hyalitis, retinal vasculitis, mainly venous and often occlusive, macular edema, and/or foci of necrotizing retinitis. Behçet's disease is a chronic disorder, characterized by a relapsing and remitting course. Male patients with younger age at onset and severe lesions at presentation are at higher risk of severe visual loss over time. The main goals in the management of patients with Behçet's disease-associated uveitis are rapid suppression of intraocular inflammation, preservation of vision, and prevention of recurrences. The treatment is based on the use of systemic glucocorticosteroids and immunosuppressive agents. Posterior segment involvement requires the use of corticosteroids and immunosuppressants, primarily azathioprine. This treatment does not appear to be sufficient for severe uveitis with reduced visual acuity or retinal vasculitis that requires anti-TNF α or interferon α. Therapeutic strategies such as TNF-alpha blockers have dramatically improved the visual prognosis of patients with intraocular inflammation related to this chronic and potentially blinding condition.
- Published
- 2018
31. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]
- Author
-
E, Diwo, P, Sève, S, Trad, P, Bielefeld, D, Sène, S, Abad, A, Brézin, P, Quartier, I, Koné Paut, M, Weber, C, Chiquet, M H, Errera, J, Sellam, P, Cacoub, G, Kaplanski, L, Kodjikian, B, Bodaghi, and D, Saadoun
- Subjects
Biological Therapy ,Uveitis ,Biological Products ,Adrenal Cortex Hormones ,Tumor Necrosis Factor-alpha ,Practice Guidelines as Topic ,Antibodies, Monoclonal ,Humans ,Expert Testimony ,Immunosuppressive Agents - Abstract
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission. Interferon is an efficient immunomodulatory treatment, as a second-line therapy, for some therapeutic indications (refractory macular edema, Behçet's vascularitis). Other biologics, especially tocilizumab, are showing promising results. Local treatments (corticosteroids, sirolimus etc.) are adjuvant therapies in case of unilateral inflammatory relapse. Therapeutic response must be evaluated precisely by clinical examination and repeated complementary investigations (laser flare photometry, multimodal imaging, perimetry, electroretinography measures).
- Published
- 2018
32. [Acute visual loss related to sphenoid meningioma]
- Author
-
H M, Le, A-L, Boch, S, Gerber, P, Cornu, B, Bodaghi, P, Lehoang, and V, Touitou
- Subjects
Male ,Acute Disease ,Skull Neoplasms ,Sphenoid Bone ,Meningeal Neoplasms ,Vision Disorders ,Humans ,Female ,Middle Aged ,Blindness ,Meningioma ,Aged - Abstract
Meningiomas represent about 20% of intracranial tumors. Involvement of the medial sphenoid wing includes anterior clinoid, cavernous sinus and superior orbital fissure meningiomas. Due to the proximity of these tumors to the optic nerve, typically progressive unilateral vision loss, over several months to years, is the classic clinical presentation. We report three cases of acute monocular vision loss, two transient and one permanent, ipsilateral to a sphenoid meningioma. Ophthalmological involvement with sphenoid meningiomas is most often chronic, due to interruption of axoplasmic flow and demyelination of the optic nerve by local compression. However, vascular involvement with ischemia of the optic nerve or transient low blood flow secondary to compression of the carotid branches vascularizing these structures is another possible mechanism. In our series, two patients had amaurosis fugax, and one patient had sudden, persistent visual loss in relation to acute anterior ischemic optic neuropathy on the side of the meningioma. The mean age of patients with acute visual manifestations was 62 years. These ischemic and non-compressive visual symptoms, ipsilateral to sphenoid meningiomas, are difficult to interpret. Whether these temporary visual disturbances of vascular origin should be considered an early sign of future severe or permanent visual impairment when no optic nerve compression is observed is not certain. The place of these acute visual disturbances in the therapeutic decision, particularly surgical, remains to be defined. Larger multicentric prospective studies are needed to better understand the role of local circulatory factors attributable to meningioma in the occurrence of these acute visual signs.
- Published
- 2018
33. Results from the SAKURA program: central retinal thickness changes with intravitreal sirolimus in subjects with non-infectious uveitis of the posterior segment and macular edema at baseline
- Author
-
B. Bodaghi and S. White
- Subjects
medicine.medical_specialty ,business.industry ,Retinal ,General Medicine ,medicine.disease ,Posterior segment of eyeball ,Ophthalmology ,chemistry.chemical_compound ,Infectious uveitis ,chemistry ,Sirolimus ,medicine ,business ,Macular edema ,medicine.drug - Published
- 2017
34. [Bilateral uveitis associated with nivolumab therapy]
- Author
-
A-L, Rémond, E, Barreau, P, Le Hoang, and B, Bodaghi
- Subjects
Uveitis ,Carcinoma, Bronchogenic ,Lung Neoplasms ,Nivolumab ,Humans ,Antineoplastic Agents ,Female ,Middle Aged - Abstract
Immune-related adverse events (IRAEs) are rare but serious adverse events that may be associated with inhibitors of few immune control points. The purpose here is to report the case of an inflammatory ocular disease, potentially linked to the immunity and use of nivolumab, a new immunological agent used for the treatment of a solid tumor. In spite of the involvement of this treatment in the onset of inflammation, we must always seek another cause. It is possible to continue this treatment by considering the benefit/risk balance for each patient. Close collaboration between oncologists and ophthalmologists is necessary in the diagnosis and rapid management of these IRAE ocular related to these new emerging therapies.
- Published
- 2017
35. [Uveitis: Diagnostic work-up. Recommendations from an expert committee]
- Author
-
P, Sève, B, Bodaghi, S, Trad, J, Sellam, D, Bellocq, P, Bielefeld, D, Sène, G, Kaplanski, D, Monnet, A, Brézin, M, Weber, D, Saadoun, P, Cacoub, C, Chiquet, and L, Kodjikian
- Subjects
Adult ,Uveitis ,Practice Guidelines as Topic ,Humans ,Mass Screening ,Diagnostic Techniques, Ophthalmological ,Child ,Expert Testimony - Abstract
Diagnostic work-up of uveitis involves many uncertainties. Search for an etiology should take into account the epidemiology of uveitis and focus on the most severe diseases or those, which can be treated. This work was undertaken to establish recommendations for the diagnosis work-up of uveitis.Recommendations were developed by a multidisciplinary panel of 15 experts, including internists, ophthalmologists and a rheumatologist and are based on a review of the literature with regard to effectiveness of investigations and the results of the ULISSE study, which is the first prospective study assessing the efficiency of a standardized strategy for the etiological diagnosis of uveitis. Children, immunocompromised patients, severe retinal vasculitis and specific ophthalmological entities are excluded from these recommendations.Investigations should be first guided by the history and physical examination. Serological screening for syphilis is the only test appropriate in all forms of uveitis. If no diagnosis is made after this stage, we propose investigations guided by the anatomic characteristics of uveitis. It includes HLA B27 testing (in unilateral acute anterior non-granulomatous uveitis), serum angiotensin converting enzyme, interferon-gamma release assay and chest CT (chronic uveitis), cerebral MRI and anterior chamber tap with IL10 analysis (intermediate or posterior uveitis in patients over 40 years). Investigations ordered in the absence of orientation are almost always unhelpful.We propose a strategy for the etiologic diagnosis of uveitis. The recommendations should be updated regularly. The efficiency of more invasive investigations has yet to be evaluated.
- Published
- 2017
36. TEMOZOLOMIDE IN RELAPSE/REFRACTORY PRIMARY VITREO-RETINAL LYMPHOMA (R/R PVRL): A SIMPLE, CHEAP, EFFECTIVE AND WELL TOLERATED TREATMENT. RESULT OF THE LARGEST STUDY ON R/R PVRL, FROM THE LOC NETWORK
- Author
-
Khê Hoang-Xuan, M. Baron, Nathalie Cassoux, Carole Soussain, Valérie Touitou, Caroline Houillier, Sylvain Choquet, Veronique Leblond, E. Gyan, Pierre Soubeyran, and B. Bodaghi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Temozolomide ,business.industry ,Hematology ,General Medicine ,Treatment results ,Refractory ,Internal medicine ,Retinal Lymphoma ,medicine ,business ,medicine.drug - Published
- 2019
37. Discussion suite à la communication : « Prise en charge diagnostique et thérapeutique des uvéites »
- Author
-
B. Bodaghi
- Subjects
General Medicine - Published
- 2019
38. [Congenital iris cyst]
- Author
-
A-L, Rémond, B, Bodaghi, and P, Le Hoang
- Subjects
Adult ,Iris Diseases ,Cysts ,Humans ,Iris ,Female ,Eye Abnormalities - Published
- 2016
39. [Birdshot retinochoroidopathy: Key messages]
- Author
-
S, Touhami, C, Fardeau, O, Zambrowski, C, Bonnet, B, Bodaghi, V, Touitou, and P, Lehoang
- Subjects
Choroiditis ,Fundus Oculi ,Multifocal Choroiditis ,Electroretinography ,Visual Acuity ,Humans ,Visual Field Tests ,Fluorescein Angiography ,Tomography, Optical Coherence - Abstract
Birdshot retinochoroidopathy (BRC) is a potentially blinding posterior autoimmune uveitis that affects Caucasian patients in their fifties. Strongly associated with the HLA A 29 phenotype, BRC is characterized by the presence of suggestive choroidal lesions on the fundus, but their apparition can be delayed. Visual acuity is not a good descriptive factor of visual function. Ancillary tests can therefore help establish the diagnosis and allow proper follow-up of BRC patients: optical coherence tomography can reveal either oedema or atrophy of the macula. Fluorescein and infracyanine green angiograms can show signs of inflammatory activity and give further diagnostic clues. Electroretinograms and visual fields can be useful for the diagnosis and follow-up. BCR patients should be examined periodically and undergo exhaustive clinical and paraclinical tests to insure the best prognosis. Corticosteroids should be associated with immunosuppressive treatments as early as possible in the presence of factors that are predictive of the worse prognoses.
- Published
- 2016
40. Les endophtalmies endogènes d’origine fongique
- Author
-
B. Bodaghi
- Subjects
Pars plana ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Panuveitis ,Vitrectomy ,medicine.disease ,Antimicrobial ,Dermatology ,Surgery ,Ophthalmology ,medicine.anatomical_structure ,Endophthalmitis ,Infectious disease (medical specialty) ,medicine ,business ,Mycosis ,Uveitis - Abstract
Endogenous endophthalmitis of bacterial or fungal origin is a rare condition, accounting for 5 to 10% of all endophthalmitis cases. Different risk factors have been identified and ocular involvement is usually due to one or multiple systemic infectious abscesses with variable virulence. Clinical symptoms may initially mimic a panuveitis and will delay diagnostic confirmation. Ancillary tests will determine the infectious source and isolate the causative agent. Specific therapy is based on systemic and intravitreal antibiotics or antifungals associated with a pars plana vitrectomy in severe cases. Despite an aggressive therapeutic strategy, visual prognosis remains guarded. Education of ophthalmologists and infectious disease specialists may decrease diagnostic delay so that specific antimicrobial agents can be initiated promptly and thus avoid a permanent blindness.
- Published
- 2011
41. Uvéites antérieures
- Author
-
H. Zeghidi, P. LeHoang, and B. Bodaghi
- Published
- 2011
42. Manifestations oculaires de la maladie de Lyme
- Author
-
B. Bodaghi
- Subjects
Pathology ,medicine.medical_specialty ,genetic structures ,business.industry ,Eye disease ,Disease ,medicine.disease ,Dermatology ,eye diseases ,Optic neuropathy ,Infectious Diseases ,Lyme disease ,Delayed hypersensitivity ,medicine ,Optic neuritis ,sense organs ,business ,Uveitis ,Antibacterial agent - Abstract
Despite the wide spectrum of clinical entities, eye involvement remains a rare event in patients with Lyme borreliosis. Most of ocular manifestations occur during the late phase of the disease. The infection needs to be considered along with more conventional causes of ocular inflammation, particularly in regions where Lyme disease is common. The pathogenesis of this condition remains controversial. Direct ocular infection and a delayed hypersensitivity mechanism may be involved at different disease stages. Uveitis and optic neuritis are the most common ocular complications. Serological testing lacks sensitivity and specificity. In atypical cases, ocular fluids sampling and analysis may be proposed. PCR seems to be an interesting diagnostic tool, allowing genotypic analysis. In the majority of cases, therapeutic strategy should be based on the association of antibiotics and corticosteroids. A new course of antibiotics may be prescribed to patients with chronic or relapsing inflammation due to bacterial persistence in ocular tissues.
- Published
- 2007
43. Retinal vasculitis
- Author
-
B. Bodaghi
- Subjects
Ophthalmology ,General Medicine - Published
- 2015
44. Long-Term Safety of Intravitreal Sirolimus for the Treatment of Non-infectious Uveitis (NIU) of the Posterior Segment: 12-Month SAKURA Study 1 Results
- Author
-
M.E. Valentine, B. Bodaghi, Carlos Pavesio, and A.C. Alfredo
- Subjects
medicine.medical_specialty ,Intraocular pressure ,genetic structures ,business.industry ,Incidence (epidemiology) ,General Medicine ,medicine.disease ,eye diseases ,law.invention ,Surgery ,Posterior segment of eyeball ,Ophthalmology ,Endophthalmitis ,Randomized controlled trial ,law ,Sirolimus ,medicine ,sense organs ,Long term safety ,Adverse effect ,business ,medicine.drug - Abstract
Purpose Intravitreal sirolimus significantly reduced inflammation in subjects with NIU of the posterior segment and provided clinically relevant visual benefit, with an acceptable incidence of ocular adverse events (AEs), in the double-masked period of SAKURA Study 1, the first of 2 phase 3 randomized trials. Here, we report the long-term (12 month) safety findings from the combined double-masked and open-label treatment periods. Methods Subjects with active NIU of the posterior segment (N = 347) were randomized to 44 μg (active control), 440 μg, or 880 μg injections of intravitreal sirolimus, administered every 2 months. At M6, all subjects transitioned to 880 µg injections every 2 months. Results 287 subjects entered the open-label treatment period and completed the M12 Vitreous Haze assessment. Of these, 211 received ≥1 intravitreal sirolimus injections. Through M12, the most common serious ocular AEs (study eye) occurring in ≥2% of subjects were ocular inflammation (2.9–5.8%), cataract (3.8%), and medication residue (transient drug depot in the visual axis; 2.3%). The mean change in intraocular pressure was
- Published
- 2015
45. Viral retinopathies: a spectrum of disease from East to West
- Author
-
B. Bodaghi
- Subjects
Ophthalmology ,General Medicine ,Disease ,Biology ,Virology - Published
- 2015
46. [Deep intracorneal foreign body: Anterior segment OCT]
- Author
-
J-L, Bacquet, A, Fel, R, Belazzougui, and B, Bodaghi
- Subjects
Adult ,Aqueous Humor ,Cornea ,Male ,Eye Foreign Bodies ,Anterior Eye Segment ,Panuveitis ,Accidents, Occupational ,Humans ,Tomography, Optical Coherence ,Aluminum - Published
- 2015
47. [Multimodal imaging of hydroxychloroquine and chloroquine retinopathy]
- Author
-
A, Sellam, N, Massamba, P, Le Hoang, and B, Bodaghi
- Subjects
Adult ,Radiography ,Lupus Erythematosus, Discoid ,Retinal Diseases ,Drug Substitution ,Humans ,Chloroquine ,Female ,Macula Lutea ,Atrophy ,Diagnostic Techniques, Ophthalmological ,Multimodal Imaging ,Hydroxychloroquine - Published
- 2015
48. Nouveaux concepts étiologiques dans l’uvéite
- Author
-
B. Bodaghi
- Subjects
Intestinal malabsorption ,Gynecology ,Ophthalmology ,medicine.medical_specialty ,business.industry ,medicine ,Whipple's disease ,Retinite ,medicine.disease ,business - Abstract
L’uveite demeure une cause importante de deficience visuelle chez les patients jeunes, en pleine activite professionnelle. Les formes idiopathiques de l’inflammation intraoculaire ne doivent plus etre considerees comme une entite presumee clinique absolue et l’ophtalmologiste doit reevaluer l’etiologie specifique d’une uveite lorsque l’examen clinique ne permet pas de mettre en evidence une cause potentielle mais aussi quand l’evolution therapeutique sous corticoides semble atypique. Les examens complementaires, en particulier les analyses serologiques, ont une portee limitee et ne doivent pas etre consideres comme une preuve absolue au cours de differentes presentations cliniques. La strategie diagnostique des uveites infectieuses a ete amelioree par l’emploi des techniques d’analyse moleculaire appliquees aux liquides et tissus oculaires. La reaction en chaine a la polymerase (PCR) est un outil diagnostique puissant qui peut etre propose en cas d’uveite ou de retinite atypique mais potentiellement infectieuses. Cette strategie est une etape majeure avant l’utilisation d’immunomodulateurs non conventionnels de nouvelle generation comme les anti-TNF alpha. Grâce a l’utilisation de procedures experimentales strictes incluant des controles adequats et reduisant les risques de contamination, la PCR et ses variantes ont modifie l’approche pratique de l’inflammation intraoculaire et ont fourni des details interessants pour une meilleure comprehension de la physiopathologie des uveites infectieuses. Le concept d’inflammation intraoculaire induite par un agent pathogene pourrait etre precise a la lumiere des resultats moleculaires obtenus a partir des liquides oculaires.
- Published
- 2005
49. Les uvéites virales
- Author
-
B. Bodaghi
- Subjects
Ophthalmology ,business.industry ,Medicine ,business ,Molecular biology - Abstract
Les maladies oculaires d’origine virale sont classiquement associees a des uveites dont les caracteristiques sont bien documentees. Cependant, les modeles experimentaux et les nouvelles donnees cliniques ont mis en evidence le role d’un agent infectieux, en particulier viral a l’origine de differentes atteintes auto immunes. L’utilisation des techniques d’analyse moleculaire est particulierement importante pour la mise en evidence du sous-groupe des uveites presumees virales mais egalement pour l’identification de virus conventionnels ou emergents responsables de formes atypiques d’uveites considerees jusqu’a present d’origine auto immune mais resistant au traitement anti-inflammatoire classique. La detection de l’ADN viral par PCR est une technique rapide, sensible et precise. L’analyse de l’humeur aqueuse pourrait etre proposee en cas d’uveite corticoresistante ou corticodependante meme si le tableau clinique n’evoque pas initialement une infection virale. La confirmation d’une etiologie infectieuse permet alors de proposer un traitement specifique et d’echapper aux differentes classes d’immunosuppresseurs. Ainsi, de nouvelles entites virales ont ete recemment identifiees comme l’uveite anterieure chronique a cytomegalovirus ou les retinopathies non-necrosantes virales chez les patients immunocompetents. Le traitement antiviral systemique doit etre propose rapidement avant meme la confirmation etiologique afin de controler la replication virale et permettre l’initiation d’une corticotherapie. Le traitement d’entretien semble reduire la frequence des rechutes.
- Published
- 2004
50. Revisiting infectious triggers of chronic intraocular immunity
- Author
-
B Bodaghi
- Subjects
Serpiginous choroiditis ,business.industry ,General Medicine ,medicine.disease_cause ,medicine.disease ,Pathogenesis ,Ophthalmology ,Molecular mimicry ,Infectious uveitis ,Antigen ,Immunity ,Immunology ,medicine ,business ,Uveitis ,Infectious agent - Abstract
The pathogenesis of intraocular inflammation has been extensively revisited on the basis of different sophisticated experimental models but also new molecular tools applied to ocular fluids or tissues. Experimental ocular inflammation may not be induced in germ-free animal facilities. Moreover, an infectious agent has been identified in patients presenting with different uveitis entities, previously considered as autoimmune and therefore treated with corticosteroids and aggressive immunosuppressive agents. Molecular mimicry or expression of foreign antigens may trigger an inflammatory reaction, masquerading as an autoimmune uveitis. Fuchs cyclitis, Posner-Schlossman syndrome, serpiginous choroiditis, nonnecrotizing herpetic retinopathies have been recently characterized, expanding the spectrum of infectious uveitis. Microbiological identification remains the first step prior to initiation of a specific therapy, reducing the risk of relapse and achieving a better visual outcome in challenging situations.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.